A Phase 1, First in Human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of NRS 033 in Healthy Volunteers
Latest Information Update: 06 Jan 2025
Price :
$35 *
At a glance
- Drugs NRS 033 (Primary)
- Indications Opioid-related disorders
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Nirsum Labs
- 01 Jan 2025 Status changed from active, no longer recruiting to completed.
- 25 Dec 2024 New trial record